TCL Secures Multiple Honors at IFA 2025 with Cutting-edge Smart-Living Solutions
BERLIN, Sept. 10, 2025 /PRNewswire/ -- TCL, a global leader in consumer…
Clearside Biomedical Announces Multiple Presentations on Suprachoroidal Delivery to be Featured at the 25th EURETINA Congress
- Presentations Highlight the Versatility of Clearside’s SCS Microinjector® Platform for the…
Hunan TV Show Singer 2025 Draws Performers from Multiple Countries
CHANGSHA, China, Aug. 4, 2025 /PRNewswire/ -- Hunan TV's Mango TV program…
China Southern Power Grid Showcases Multiple AI Achievements at 2025 World Artificial Intelligence Conference
SHANGHAI, July 30, 2025 /PRNewswire/ -- From July 26 to 28, the 2025…
FROM THE ALZHEIMER’S ASSOCIATION INTERNATIONAL CONFERENCE 2025: U.S. POINTER STUDY SHOWS STRUCTURED LIFESTYLE PROGRAM TARGETING MULTIPLE RISK FACTORS IMPROVES COGNITION IN OLDER ADULTS AT RISK OF COGNITIVE DECLINE
Key Takeaways Two lifestyle interventions in U.S. POINTER improved cognition in older…
Press Release: Sanofis Sarclisa approved in the EU for the treatment of transplant-eligible newly diagnosed multiple myeloma
Sanofi’s Sarclisa approved in the EU for the treatment of transplant-eligible newly…
Chambers and Partners Research Yields Multiple Global Honors for J.S. Held Experts
JERICHO, N.Y., June 26, 2025 /PRNewswire/ -- Global consulting firm J.S. Held…
EHA 2025 | Multiple Studies Report Encouraging Data of Olverembatinib in Ph+ ALL
ROCKVILLE, Md. and SUZHOU, China, June 15, 2025 (GLOBE NEWSWIRE) -- Ascentage…
Investigational combination of first-in-class bispecific antibodies TALVEY (talquetamab) and TECVAYLI (teclistamab) shows deep and durable responses in heavily pretreated multiple myeloma patients with extramedullary disease
Results from the Phase 2 RedirecTT-1 study demonstrate deep responses with 78.9…
Persistent Achieves Top Rankings for the Second Year in a Row in Extel’s Asia Executive Team Survey
Recognized under multiple categories, including Best CEO, Company Board of Directors, Overall…
